Cardiac resynchronization improved symptoms, quality of life, and reduced death risk in heart failure patients, complementing standard pharmacologic therapy.
Does cardiac resynchronization reduce the composite of death or unplanned hospitalization for a major cardiovascular event in patients with NYHA class III/IV heart failure, left ventricular systolic dysfunction, and cardiac dyssynchrony?
In patients with moderate or severe heart failure and cardiac dyssynchrony, adding cardiac resynchronization to standard pharmacologic therapy significantly reduces the risk of death and major cardiovascular hospitalizations.
Absolute Event Rate: 0% vs 0%
In patients with heart failure and cardiac dyssynchrony, cardiac resynchronization improves symptoms and the quality of life and reduces complications and the risk of death. These benefits are in addition to those afforded by standard pharmacologic therapy. The implantation of a cardiac-resynchronization device should routinely be considered in such patients.
Cleland et al. (Mon,) reported a other. Cardiac resynchronization improved symptoms, quality of life, and reduced death risk in heart failure patients, complementing standard pharmacologic therapy.